51 related articles for article (PubMed ID: 23610449)
21. Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Prescrire Int; 2012 Jun; 21(128):147-9. PubMed ID: 22822591
[TBL] [Abstract][Full Text] [Related]
22. Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate-resistant prostate cancer.
Thomson D; Charnley N; Parikh O
Eur J Cancer; 2014 Mar; 50(5):1040-1. PubMed ID: 24462374
[No Abstract] [Full Text] [Related]
23. Abiraterone and MVD3100 take androgen deprivation to a new level.
Schmidt C
J Natl Cancer Inst; 2011 Feb; 103(3):175-6. PubMed ID: 21242338
[No Abstract] [Full Text] [Related]
24. Abiraterone acetate.
Logothetis CJ; Efstathiou E; Manuguid F; Kirkpatrick P
Nat Rev Drug Discov; 2011 Aug; 10(8):573-4. PubMed ID: 21804589
[No Abstract] [Full Text] [Related]
25. A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.
Varkaris A; Stevens J; Ono Y; Balk SP; Bellmunt J
JCO Precis Oncol; 2022 Feb; 6():e2100091. PubMed ID: 35201849
[No Abstract] [Full Text] [Related]
26. UT-34: a promising new AR degrader.
Stone L
Nat Rev Urol; 2019 Nov; 16(11):640. PubMed ID: 31578494
[No Abstract] [Full Text] [Related]
27. MDV3100: Tritium labeling at high specific activity.
Byon C; Chakravarty S; Filer CN; Jain R; Maniscalco MP
Appl Radiat Isot; 2016 Feb; 108():35-37. PubMed ID: 26686973
[TBL] [Abstract][Full Text] [Related]
28. Reply to K.S. Shohdy et al.
Traina TA; Cortes J
J Clin Oncol; 2018 Aug; 36(23):2458-2459. PubMed ID: 29847296
[No Abstract] [Full Text] [Related]
29. Is the Clinical Benefit Rate at Sixteen Weeks a Reliable End Point?
Shohdy KS; Kassem L; Mangalik A
J Clin Oncol; 2018 Aug; 36(23):2457-2458. PubMed ID: 29847293
[No Abstract] [Full Text] [Related]
30. The effect of exposure to two odorous compounds (pheromones) on an assessment of people test.
Cowley JJ; Brooksbank BW
Prog Brain Res; 1975; 42():375-6. PubMed ID: 1239046
[No Abstract] [Full Text] [Related]
31. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
[TBL] [Abstract][Full Text] [Related]
32. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.
Zhang W; Wu TY; Chen Q; Shi XL; Xiao GA; Zhao L; Xu CL; Zhou T; Sun YH
Asian J Androl; 2017; 19(2):196-202. PubMed ID: 27212123
[TBL] [Abstract][Full Text] [Related]
33. Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy.
Narayanan S; Srinivas S; Feldman D
Nat Rev Urol; 2016 Jan; 13(1):47-60. PubMed ID: 26643568
[TBL] [Abstract][Full Text] [Related]
34. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
End D; Molina A; Todd M; Meyers ML
Cancer Res; 2013 May; 73(9):2926. PubMed ID: 23610449
[No Abstract] [Full Text] [Related]
35. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J; Lim AC; Hay CW; Taylor AE; Wingate A; Nowakowska K; Pezaro C; Carreira S; Goodall J; Arlt W; McEwan IJ; de Bono JS; Attard G
Cancer Res; 2012 May; 72(9):2176-82. PubMed ID: 22411952
[TBL] [Abstract][Full Text] [Related]
36. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Anand AU; Bjartell A
Eur Urol; 2015 Feb; 67(2):349-50. PubMed ID: 25760252
[No Abstract] [Full Text] [Related]
37. Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Taneja SS
J Urol; 2015 Feb; 193(2):538. PubMed ID: 25617272
[No Abstract] [Full Text] [Related]
38. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.
Agarwal N; Hutson TE; Vogelzang NJ; Sonpavde G
Future Oncol; 2010 May; 6(5):665-79. PubMed ID: 20465382
[TBL] [Abstract][Full Text] [Related]
39. The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Beatty J; Bell R; Miller M
Expert Rev Anticancer Ther; 2012 Apr; 12(4):429-37. PubMed ID: 22500680
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
